Evidence map›Paper›PMID 26905068›Full record

ArticleFamilial cancer2016

Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India.

Manjunath Goroshi, Tushar Bandgar, Anurag R Lila, Swati Sachin Jadhav, Shruti Khare, Shailesh V Shrikhande, Shinya Uchino, Abhay N Dalvi, Nalini S Shah

Abstract read
PubMed Publisher
In one paragraph

Article in Familial cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Approach to the Patient With Prolactinoma.The Journal of clinical endocrinology and metabolism · 2023
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Neuroendocrine neoplasm: Current understanding.Journal of postgraduate medicine
    Article
  9. Targeted Next-Generation Sequencing ofIndian journal of endocrinology and metabolism
    Article
  10. Comparison ofWorld journal of nuclear medicine
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Manjunath GoroshiDepartment of Endocrinology, Seth G S Medical College, KEM Hospital, Parel, Mumbai, 400012, India. manjunath.r.goroshi@gmail.com.
Tushar BandgarDepartment of Endocrinology, Seth G S Medical College, KEM Hospital, Parel, Mumbai, 400012, India.
Anurag R LilaDepartment of Endocrinology, Seth G S Medical College, KEM Hospital, Parel, Mumbai, 400012, India.
Swati Sachin JadhavDepartment of Endocrinology, Seth G S Medical College, KEM Hospital, Parel, Mumbai, 400012, India.
Shruti KhareDepartment of Endocrinology, Seth G S Medical College, KEM Hospital, Parel, Mumbai, 400012, India.
Shailesh V ShrikhandeGI and HPB Surgery, Department of Surgical Oncology, TATA Memorial Hospital, Mumbai, India.
Shinya UchinoSurgical Department, Noguchi Thyroid Clinic and Hospital Foundation, 7-52 Aoyama, Beppu, Oita, 874-0902, Japan.
Abhay N DalviDepartment of Surgery, Seth G S Medical College, Mumbai, India.
Nalini S ShahDepartment of Endocrinology, Seth G S Medical College, KEM Hospital, Parel, Mumbai, 400012, India.
College of Medicine & JNM Hospital · INKing Edward Memorial Hospital and Seth G.S. Medical College · INNoguchi Thyroid Clinic and Hospital Foundation · JPTata Memorial Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple endocrine neoplasia type 1 syndrome (MEN1) is a rare autosomal dominant familial cancer syndrome affecting multiple endocrine glands. Published literature on MEN1 from Indian subcontinent is scarce. We report here a case series of MEN1 patients (n = 18) from 14 unrelated families. Retrospective study describing the clinical profile of MEN1 patients from endocrine unit of a tertiary care hospital from western India. Additionally clinical profile of primary hyperparathyroidism (PHPT) in MEN1 patients was compared with that of apparently sporadic PHPT cohort from our centre. Eighteen patients (10 males, 8 females) diagnosed as MEN1 were included. Mean age at diagnosis was 31.5 ± 10.6 years (range 17-54). Incidence of primary hyperparathyroidism (PHPT), pituitary adenoma (PA), and gastro-entero-pancreatic neuroendocrine tumor (GEP-NET) was 94.4, 72.2, and 72.2 %, respectively. GEP-NET was the commonest presenting lesion (33.3 %), followed by PA (27.7 %), PHPT (16.6 %), thymic carcinoid (5.5 %), while 16.6 % cases were identified on family screening. PHPT manifestations (clinical and biochemical) in MEN1 were less severe as compared to those of sporadic PHPT. Contrast enhanced computed tomography (CECT) and (68)Ga-DOTANOC PET/CT were equally sensitive (64.7 vs. 63.5 %) in identifying multiglandular parathyroid disease. Non functioning tumors (NFT) were the most common GEP-NET, followed by insulinoma (5/13, two were metastatic). (68)Ga-DOTANOC PET/CT had higher sensitivity in detecting GEP-NET lesions than CECT (100 vs. 62.5 %). The most common pituitary lesion was prolactinoma, and all were cabergoline responsive. Genetic analysis was available in 13 patients and 11 patients showed mutation in MEN1 gene. The clinical profile of MEN1 in Asian Indian patients is largely comparable to that reported in other cohorts. Peculiar findings of our cohort are predominance of GEP-NET as a presenting manifestation and relatively higher prevalence of insulinoma with higher occurrence of metastatic insulinoma. Clinical and biochemical profile of MEN1 associated PHPT is less severe than that of our sporadic PHPT.

Indexed as

AdolescentAdultFemaleHumansHyperparathyroidism, PrimaryIndiaMaleMiddle AgedMultiple Endocrine Neoplasia Type 1Neuroendocrine TumorsPositron Emission Tomography Computed TomographyProto-Oncogene ProteinsYoung AdultMEN1 protein, humanProto-Oncogene ProteinsMEN1 syndromeNETPituitary adenomaPrimary hyperparathyroidism

Identifiers

PMID26905068
OpenAlexW2274447308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.